USE OF AGE-SPECIFIC NORMAL RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN

Background.-The traditional normal range for prostate-specific antigen has been 0.0 to 4.0 ng/mL. Two different age-specific normal ranges h ave been proposed, one by Oesterling et al and the other generated by the Prostate Cancer Awareness Week experience. Methods.-We studied 213 consecutive cases of biopsy-proven prostate adenocarcinoma to evaluat e age-specific normal ranges for prostate-specific antigen. We examine d each patient's age, stage of disease, and serum concentration of pro state-specific antigen at the time of diagnosis. The three normal rang es were applied to each case. Results.-The patients ranged in age from 45 to 87 years. At all stages of disease, more patients had elevated serum prostate-specific antigen values using the traditional normal ra nge as opposed to either age-specific normal range. These discrepancie s were most obvious for stage II disease, in which 93 of 119 cases (78 %) were elevated according to the traditional normal range versus 78 o f 119 cases (66%) according to the Oesterling et al range and 80 of 11 9 cases (67%) according to the range defined during Prostate Cancer Aw areness Week. For patients aged 40 to 59 years, all three normal range s provided identical results (18 of 22 [82%] cancers detected). Conclu sions.-Use of either age-specific normal range would have missed more than 10% of stage II prostate adenocarcinomas in patients over the age of 60 years. This indicates that caution should be exercised when app lying age-adjusted normal ranges for serum concentrations of prostate- specific antigen in patients of that age group.